Literature DB >> 8634692

Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Clinical Research Group for VHL in Japan.

.   

Abstract

The von Hippel-Lindau disease (VHL) gene is a putative tumor suppressor gene responsible for VHL, an autosomal dominantly inherited multitumor syndrome. It is also implicated in the development of sporadic tumors including clear cell renal carcinoma and central nervous system hemangioblastoma. To define the molecular basis of VHL patients in Japanese populations, we tested for germline mutations of the VHL gene in 45 unrelated Japanese VHL patients by single-strand conformation polymorphism (SSCP) analysis and Southern blot analysis. We detected 23 (51%) intragenic mutations and three (6.7%) deletions by SSCP analysis and Southern blot respectively. The intragenic mutations consisted of 14 missense mutations, seven microdeletions or insertions and two splice-site mutations. Interestingly, nine of 10 mutations in exon 1 are localized in a short region of 37 nucleotides. Five unique sites of mutation were included, which were not seen in previous studies. Unlike Western VHL patients, nonsense mutations were not found in Japanese VHL patients. If the presence of pheochromocytomas is regarded as phenotypic marker for VHl classification, the mutations found in 22 VHL patients without pheochromocytoma consisted of 11 missense mutations, six microdeletions or insertions, two splice-site alterations and three deletions. The mutations found in four VHL patients with pheochromocytomas consisted of one missense mutation at nucleotide 683 (codon 228), two missense mutations at nucleotide 712 (codon 238) and a novel 20 bp insertion at nucleotide 776 (codon 259). Although the mutations at codon 238 are the mutational hot spot found in Western VHL patients with pheochromocytomas, a 20 bp insertion of original VHL cDNA sequence, from nucleotide 777 to 796, is a unique mutation. Our results suggest that mutations in Japanese VHL patients contain some unique features compared with those in Western patients. VHL gene has a critical role for the etiology in VHL in Japanese populations as well as Western VHL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634692     DOI: 10.1093/hmg/4.12.2233

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

1.  Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.

Authors:  R Rajasekaran; C Sudandiradoss; C George Priya Doss; Anshuman Singh; Rao Sethumadhavan
Journal:  Mamm Genome       Date:  2008-10-03       Impact factor: 2.957

2.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

3.  Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Authors:  Sena Hwang; Cheol Ryong Ku; Ji In Lee; Kyu Yeon Hur; Myung-Shik Lee; Chul-Ho Lee; Kyo Yeon Koo; Jin-Sung Lee; Yumie Rhee
Journal:  J Hum Genet       Date:  2014-07-31       Impact factor: 3.172

4.  Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma.

Authors:  Gergely Losonczy; Ferenc Fazakas; György Pfliegler; István Komáromi; Erzsébet Balázs; Krisztina Pénzes; András Berta
Journal:  BMC Med Genet       Date:  2013-01-08       Impact factor: 2.103

Review 5.  Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T).

Authors:  Daniela Alosi; Marie Luise Bisgaard; Sophie Nowak Hemmingsen; Lotte Nylandsted Krogh; Hanne Birte Mikkelsen; Marie Louise Mølgaard Binderup
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

6.  Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families.

Authors:  M Yoshida; S Ashida; K Kondo; K Kobayashi; H Kanno; N Shinohara; N Shitara; T Kishida; S Kawakami; M Baba; I Yamamoto; M Hosaka; T Shuin; M Yao
Journal:  Jpn J Cancer Res       Date:  2000-02

7.  Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis.

Authors:  Hyun-Jung Cho; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

Review 8.  Early identification of patients with von Hippel-Lindau disease at risk for pheochromocytoma.

Authors:  J K Maranchie; M M Walther
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 2.862

9.  E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.

Authors:  Kyeong-Su Park; Ju Hee Kim; Hee Won Shin; Kyung-Sook Chung; Dong-Soo Im; Jung Hwa Lim; Cho-Rok Jung
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.